{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:49:08Z","timestamp":1789213748755,"version":"build-2803163510"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jsat.2022.108923","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T18:27:47Z","timestamp":1667068067000},"page":"108923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["National trends in buprenorphine prescribing before and during the COVID-19 pandemic"],"prefix":"10.1016","volume":"144","author":[{"given":"Mir M.","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy B.","family":"Creedon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Jacobus-Kantor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tisamarie B.","family":"Sherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2022.108923_bb0005","article-title":"Medicaid expansion and drug overdose mortality during the COVID-19 pandemic in the United States [published online ahead of print, 2022 feb 2]","volume":"232","author":"Auty","year":"2022","journal-title":"Drug and Alcohol Dependence"},{"issue":"9","key":"10.1016\/j.jsat.2022.108923_bb0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.2487","article-title":"Trends in US health insurance coverage during the COVID-19 pandemic","volume":"2","author":"Bundorf","year":"2021","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.jsat.2022.108923_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108384","article-title":"Use of buprenorphine for those with employer-sponsored insurance during the initial phase of the COVID-19 pandemic","volume":"129","author":"Cantor","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2022.108923_bb0020","series-title":"Overdose deaths accelerating during COVID-19","year":"2020"},{"key":"10.1016\/j.jsat.2022.108923_bb0035","author":"Center for Medicare and Medicaid Services"},{"key":"10.1016\/j.jsat.2022.108923_bb2005","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109192","article-title":"Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex - United States, March 2019 - December 2020","volume":"232","author":"Cremer","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"10.1016\/j.jsat.2022.108923_bb0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.6147","article-title":"Prescribing of opioid analgesics and buprenorphine for opioid use disorder during the COVID-19 pandemic","volume":"4","author":"Currie","year":"2021","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.jsat.2022.108923_bb0045","series-title":"U.S. Department of Health and Human Services Overdose Prevention Strategy (Issue Brief)","author":"Haffajee","year":"2021"},{"issue":"10","key":"10.1016\/j.jsat.2022.108923_bb0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.29409","article-title":"Trends in and characteristics of buprenorphine misuse among adults in the US","volume":"4","author":"Han","year":"2021","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.jsat.2022.108923_bb0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jsat.2018.12.006","article-title":"Behavioral health treatment utilization among individuals with co-occurring opioid use disorder and mental illness: Evidence from a national survey","volume":"98","author":"Novak","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"4","key":"10.1016\/j.jsat.2022.108923_bb0060","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1001\/jamainternmed.2020.7497","article-title":"Assessment of filled buprenorphine prescriptions for opioid use disorder during the coronavirus disease 2019 pandemic","volume":"181","author":"Nguyen","year":"2021","journal-title":"JAMA Internal Medicine"},{"issue":"6","key":"10.1016\/j.jsat.2022.108923_bb0065","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.14765","article-title":"Racial and ethnic disparities in buprenorphine and extended-release naltrexone filled prescriptions during the COVID-19 pandemic","volume":"5","author":"Nguyen","year":"2022","journal-title":"JAMA Network Open"},{"issue":"11","key":"10.1016\/j.jsat.2022.108923_bb0070","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.3833","article-title":"Assessment of state and federal health policies for opioid use disorder treatment during the COVID-19 pandemic and beyond","volume":"2","author":"Pessar","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"1","key":"10.1016\/j.jsat.2022.108923_bb0075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMp1804059","article-title":"Moving addiction care to the mainstream - Improving the quality of buprenorphine treatment","volume":"379","author":"Saloner","year":"2018","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"10.1016\/j.jsat.2022.108923_bb0080","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1176\/appi.ps.202000725","article-title":"COVID-19, structural racism, and mental health inequities: Policy implications for an emerging syndemic","volume":"72","author":"Shim","year":"2021","journal-title":"Psychiatric Services (Washington, D.C.)"},{"issue":"1","key":"10.1016\/j.jsat.2022.108923_bb0085","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1377\/hlthaff.2018.05145","article-title":"Trends in buprenorphine prescribing by physician specialty","volume":"38","author":"Wen","year":"2019","journal-title":"Health Affairs (Millwood)"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547222002057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547222002057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:58:06Z","timestamp":1760039886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547222002057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":16,"alternative-id":["S0740547222002057"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2022.108923","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"National trends in buprenorphine prescribing before and during the COVID-19 pandemic","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2022.108923","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108923"}}